Listed on the NASDAQ Market since 1992, we are committed to       balancing our standards of scientific rigor and clinical integrity with our       corporate imperatives of value creation and long-term business       sustainability.

Webcast ImageWebcast
2015 BIO CEO & Investor Conference (Live)
02/09/15 at 8:30 a.m. ET
Corporate Profile

StemCells, Inc. is poised to be among the first to market stem cell-based therapeutic products to treat diseases and disorders of the central nervous system (CNS). The Company’s proprietary HuCNS-SC® (purified human neural stem cells) platform technology is currently in clinical development for spinal cord injury (SCI) and age-related macular degeneration (AMD). Expandable and bankable, HuCNS-SC cells can ultimately be "manufactured" at commercial-scale as "stem cells in a bottle," then distributed for patient doses, much like an off-the-shelf pharmaceutical product.
More >>

Learn more about What Sets Us Apart.

StemCells, Inc. has been listed on the NASDAQ Market since 1992.
Download Documentation StemCells, Inc. Investor and Analyst Event
Get help downloading or viewing the above file types
CEO Podcast
10/15/2014  Martin McGlynn Interview on BioTech Nation Radio
Letter to Investors
January 26, 2015  Letter to Investors from CEO Martin McGlynn
Recent News
01/26/15Stem Cells Inc. Posts Letter to Shareholders
NEWARK, Calif., Jan. 26, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, posted today the following Letter to Shareholders from its President and CEO, Martin McGlynn. January 26, 2015 Dear Fellow Shareholders: Over the past year, StemCells, Inc. has made substantial progress. We completed enrollment and dosing in our Phase I/II clinical trials in two major indicat... 
Printer Friendly Version
12/18/14StemCells, Inc. Transplants First Participant in Phase II Clinical Trial in Cervical Spinal Cord Injury
Pathway Study to Assess the Potential of Human Neural Stem Cells to Restore Motor Function NEWARK, Calif., Dec. 18, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, announced today that it has transplanted the first subject in its Phase II Pathway® Study assessing the efficacy of its proprietary HuCNS-SC® (purified human neural stem cells) platform techn... 
Printer Friendly Version
12/02/14StemCells, Inc. Hosts Leading Biotech Investors and Analysts at Inaugural Event
NEWARK, Calif., Dec. 2, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leader in the development of cell-based therapies for disorders of the central nervous system (CNS), hosted its first investor and analyst event in New York, on November 20, 2014. The event was well-attended by biotech investing VIPs including representatives from Maxim Group, Piper Jaffray, Brinson Patrick Securities, Needham and Company, H.C. Wainwright and Company, Cantor Fitzgerald, Ladenburg Thalmann and M... 
Printer Friendly Version
11/20/14StemCells, Inc. to Host Inaugural Investor and Analyst Event in New York
NEWARK, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), who pioneered the discovery and development of HuCNS-SC® cells, a proprietary population of highly purified, expandable human neural stem cells and is leading the development of cell based therapies for the treatment of disorders of the central nervous system, will host its first investor and analyst event today, November 20, 2014, in New York. The program will feature a keynote address from Irving L. Weissman M... 
Printer Friendly Version
More >>
Upcoming Events
2015 BIO CEO & Investor Conference
LocationNew York, NY
GTC Stem Cell Summit 2015
LocationBoston, MA
More >>
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever StemCells, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Enter your e-mail address here:

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Stock Quote
STEM (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.05 (4.59%)
Data as of 01/30/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Analyst Coverage

Click here for a list of analysts covering StemCells, Inc.

Primary IR Contact

Greg Schiffman
StemCells, Inc.
7707 Gateway Blvd
Newark, CA 94560
Phone: 510.456.4128
Fax: 650.475.3101
Contact by e-mail

Investor Tools
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet